35082602 27102170 31970201 18401432 26958729 24548049 22348550 26611604 32632432 28284394 22447154 26830550 19774456 26456498 18668342 19155540 20123463 22107842 30742839 20123477 26909355 18502400 - Search Results

Year	Number of Results
2008	3
2009	3
2010	3
2012	3
2014	2
2015	1
2016	5
2019	2
2020	2
2021	1
2022	1
2023	0

1

Engineering Organoids for in vitro Modeling of Phenylketonuria.

Borges AC, Broersen K, Leandro P, Fernandes TG. Borges AC, et al. Front Mol Neurosci. 2022 Jan 10;14:787242. doi: 10.3389/fnmol.2021.787242. eCollection 2021. Front Mol Neurosci. 2022. PMID: 35082602 Free PMC article. Review.

2

A Specific Nutrient Combination Attenuates the Reduced Expression of PSD-95 in the Proximal Dendrites of Hippocampal Cell Body Layers in a Mouse Model of Phenylketonuria.

Bruinenberg VM, van Vliet D, Attali A, de Wilde MC, Kuhn M, van Spronsen FJ, van der Zee EA. Bruinenberg VM, et al. Nutrients. 2016 Mar 26;8(4):185. doi: 10.3390/nu8040185. Nutrients. 2016. PMID: 27102170 Free PMC article.

3

AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.

Richards DY, Winn SR, Dudley S, Nygaard S, Mighell TL, Grompe M, Harding CO. Richards DY, et al. Mol Ther Methods Clin Dev. 2019 Dec 24;17:234-245. doi: 10.1016/j.omtm.2019.12.004. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2019. PMID: 31970201 Free PMC article.

4

Potential of AAV vectors in the treatment of metabolic disease.

Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Alexander IE, et al. Gene Ther. 2008 Jun;15(11):831-9. doi: 10.1038/gt.2008.64. Epub 2008 Apr 10. Gene Ther. 2008. PMID: 18401432 Review.

5

AAV-Mediated Gene Therapy for Research and Therapeutic Purposes.

Samulski RJ, Muzyczka N. Samulski RJ, et al. Annu Rev Virol. 2014 Nov;1(1):427-51. doi: 10.1146/annurev-virology-031413-085355. Annu Rev Virol. 2014. PMID: 26958729

6

Altered brain protein expression profiles are associated with molecular neurological dysfunction in the PKU mouse model.

Imperlini E, Orrù S, Corbo C, Daniele A, Salvatore F. Imperlini E, et al. J Neurochem. 2014 Jun;129(6):1002-12. doi: 10.1111/jnc.12683. Epub 2014 Mar 24. J Neurochem. 2014. PMID: 24548049 Free PMC article.

7

Reversal of metabolic and neurological symptoms of phenylketonuric mice treated with a PAH containing helper-dependent adenoviral vector.

Cerreto M, Mehdawy B, Ombrone D, Nisticò R, Ruoppolo M, Usiello A, Daniele A, Pastore L, Salvatore F. Cerreto M, et al. Curr Gene Ther. 2012 Feb 1;12(1):48-56. doi: 10.2174/156652312799789280. Curr Gene Ther. 2012. PMID: 22348550

8

Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Gessler DJ, Gao G. Gessler DJ, et al. Methods Mol Biol. 2016;1382:429-65. doi: 10.1007/978-1-4939-3271-9_30. Methods Mol Biol. 2016. PMID: 26611604 Free PMC article. Review.

9

Half a century of amyloids: past, present and future.

Ke PC , Zhou R , Serpell LC , Riek R , Knowles TPJ , Lashuel HA , Gazit E , Hamley IW , Davis TP , Fändrich M , Otzen DE , Chapman MR , Dobson CM , Eisenberg DS , Mezzenga R . Ke PC , et al. Chem Soc Rev. 2020 Aug 7;49(15):5473-5509. doi: 10.1039/c9cs00199a. Epub 2020 Jul 7. Chem Soc Rev. 2020. PMID: 32632432 Free PMC article. Review.

10

Impaired Neurotransmission in Early-treated Phenylketonuria Patients.

González MJ, Gassió R, Artuch R, Campistol J. González MJ, et al. Semin Pediatr Neurol. 2016 Nov;23(4):332-340. doi: 10.1016/j.spen.2016.11.007. Epub 2016 Nov 9. Semin Pediatr Neurol. 2016. PMID: 28284394 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results